Yu H C, Chan T Y, Critchley J A, Woo K S
Department of Medicine, Chinese University of Hong Kong.
QJM. 1996 Feb;89(2):127-35. doi: 10.1093/qjmed/89.2.127.
Chinese patients are reportedly more sensitive than Caucasians to the anticoagulant effect of warfarin. We examined warfarin dose requirements and their determinants in 151 Chinese out-patients on stable maintenance dose of warfarin with international normalized ratio of 2 to 2.5. Mean daily warfarin requirement was 3.3 +/- 1.4 mg, much lower than reported doses in Caucasian patients. The most important determinant was age (r = -0.43, p < 0.001), with progressively lower warfarin requirement with increasing age (p = 0.0001). There was a weaker association with body weight (r = 0.20, p = 0.01). Patients with chronic rheumatic heart disease tended to require a smaller dose than those with heart valve replacements (2.94 +/- 1.24 vs. 3.69 +/- 1.42 mg, p < 0.01). We confirm that Chinese patients require a smaller dose of warfarin for the same degree of anticoagulation. Age is the most important factor affecting dose requirement, although body weight and underlying disease also play a role.
据报道,中国患者对华法林的抗凝作用比白种人更敏感。我们研究了151名接受华法林稳定维持剂量治疗且国际标准化比值为2至2.5的中国门诊患者的华法林剂量需求及其决定因素。华法林的平均每日需求量为3.3±1.4毫克,远低于白种人患者的报告剂量。最重要的决定因素是年龄(r = -0.43,p < 0.001),随着年龄增长,华法林需求量逐渐降低(p = 0.0001)。与体重的关联较弱(r = 0.20,p = 0.01)。慢性风湿性心脏病患者所需剂量往往比心脏瓣膜置换患者小(2.94±1.24对3.69±1.42毫克,p < 0.01)。我们证实,对于相同程度的抗凝,中国患者需要较小剂量的华法林。年龄是影响剂量需求的最重要因素,尽管体重和基础疾病也起作用。